Posted by Michael Wonder on 02 Mar 2022
Advanced Innovative Partners announces designation for rare paediatric disease drug
1 March 2022 - AIP is pleased to announce that the U.S Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designation to a radiopharmaceutical for Positron Emission Tomography (PET) diagnosis and clinical management of pediatric patients with Atypical Teratoid Rhabdoid Tumors (AT/RT).
Atypical teratoid/rhabdoid tumor (AT/RT) is a very rare, clinically aggressive fast-growing tumor of the brain and spinal cord that most often affects children aged 3 years and younger but can occur in older children.
